165 results
8-K
NMTRQ
9 Meters Biopharma, Inc.
30 May 23
9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome
4:11pm
(the “Separation Agreement”). Pursuant to the Separation Agreement, Mr. Temperato will be entitled to severance benefits including payment of his annual
8-K
EX-10.1
NMTRQ
9 Meters Biopharma, Inc.
30 May 23
9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome
4:11pm
offered, and Executive has accepted, the terms of this Agreement providing certain severance benefits to Executive.
NOW THEREFORE, in consideration … of the benefits provided to Executive herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged
8-K
EX-10.1
m8khju2d7hby8nv1tv
6 Oct 22
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-99.1
2loal
26 Sep 22
9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA
4:08pm
8-K
EX-10.2
cf6s2jpnl0eu77qwxl
30 Jun 22
9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome
8:18am
8-K
EX-10.1
4sojztdxj ubs2kbif
30 Jun 22
9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome
8:18am
8-K
EX-99.2
p2hqefc 35e552q3
30 Jun 22
9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome
7:06am
8-K
EX-10.1
y0cx1yu8ut6y agn
22 Jun 22
Departure of Directors or Certain Officers
4:51pm
8-K
EX-10.2
5x7lc44cnfmj mpm87
18 Jan 22
9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer
8:05am